ChiCTR2500096828 版本V1.0 版本创建时间2025/02/07 10:42:29 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500096828 

最近更新日期:

Date of Last Refreshed on:

2025-02-07 10:42:21 

注册时间:

Date of Registration:

2025-02-07 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

线上线下一体化体质量管理模式在超重或肥胖孕妇中的应用

Public title:

Application of integrated online and offline quality management mode in overweight or obese pregnant women

注册题目简写:

English Acronym:

研究课题的正式科学名称:

线上线下一体化体质量管理模式在超重或肥胖孕妇中的应用

Scientific title:

Application of integrated online and offline quality management mode in overweight or obese pregnant women

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

邵清春 

研究负责人:

邵清春 

Applicant:

Shao Qingchun 

Study leader:

Shao Qingchun 

申请注册联系人电话:

Applicant telephone:

+86 13780822829

研究负责人电话:

Study leader's
telephone:

+86 536 3081666

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

13780822829@163.com

研究负责人电子邮件:

Study leader's E-mail:

13780822829@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省潍坊市奎文区虞河路2428号

研究负责人通讯地址:

山东省潍坊市奎文区虞河路2428号

Applicant address:

No. 2428 Yuhe Road, Kuiwen District, Weifang City, Shandong Province

Study leader's address:

No.2428 Yuhe Road, Kuiwen District, Weifang City, Shandong Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

潍坊医学院附属医院

Applicant's institution:

Weifang Medical University Affiliated Hospital

研究负责人所在单位:

山东第二医科大学附属医院

Affiliation of the Leader:

The Affiliated Hospital of Weifang Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY-2024-M76

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

潍坊医学院附属医院医学伦理委员会

Name of the ethic committee:

Affiliated Hospital of WFMU ethics committee for clinical research

伦理委员会批准日期:

Date of approved by ethic committee:

2024-08-08 00:00:00

伦理委员会联系人:

张志英

Contact Name of the ethic committee:

Zhang Zhiying

伦理委员会联系地址:

山东省潍坊市奎文区虞河路2428号

Contact Address of the ethic committee:

No.2428 Yuhe Road, Kuiwen District, Weifang City, Shandong Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 536 3081125

伦理委员会联系人邮箱:

Contact email of the ethic committee:

wyfykyk@163.com

研究实施负责(组长)单位:

山东第二医科大学附属医院

Primary sponsor:

The Affiliated Hospital of Weifang Medical University

研究实施负责(组长)单位地址:

山东省潍坊市奎文区虞河路2428号

Primary sponsor's address:

No.2428 Yuhe Road, Kuiwen District, Weifang City, Shandong Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

Country:

China

Province:

Shandong

City:

单位(医院):

山东第二医科大学附属医院

具体地址:

山东省潍坊市奎文区虞河路2428号

Institution
hospital:

The Affiliated Hospital of Weifang Medical University

Address:

No.2428 Yuhe Road, Kuiwen District, Weifang City, Shandong Province

经费或物资来源:

潍坊市卫生健康委员会

Source(s) of funding:

Weifang Municipal Health Commission

研究疾病:

超重和肥胖孕产妇  

Target disease:

Overweight and obese pregnant women

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究的开展可以帮助超重或肥胖孕妇将孕期体重增长速度控制在适宜范围内,有利于提高阴道自然分娩率,降低剖宫产率,减少妊娠期糖尿病发生的风险;同时有利于将新生儿出生体重控制在理想范围内,减少巨大儿、新生儿低血糖等的发生,此外还可减轻产科医护工作者的工作负担,提升工作质量。  

Objectives of Study:

The development of this study can help overweight or obese pregnant women to control the growth rate of weight during pregnancy in an appropriate range, which is conducive to improving the natural vaginal delivery rate, reducing the cesarean section rate, and reducing the risk of diabetes during pregnancy; At the same time, it is beneficial to control the birth weight of newborns within the ideal range, reduce the occurrence of macrosomia, neonatal hypoglycemia, etc. In addition, it can also reduce the workload of obstetric medical workers and improve work quality.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.孕12-14周在潍坊医学院附属医院产科门诊建档的孕妇; 2.B超确诊为单胎妊娠; 3.18岁<=年龄<=35岁; 4.孕前24.0<=BMI<=32.0。

Inclusion criteria

1. Pregnant women who are 12-14 weeks pregnant and have a file in the obstetric outpatient clinic of the Affiliated Hospital of Weifang Medical College; 2. B ultrasound confirmed singleton pregnancy; 3. 18 years old< = age< = 35 years; 4. Pre-pregnancy 24.0<=BMI<=32.0.

排除标准:

1.胎儿畸形; 2.既往有习惯性流产、合并子痫前期等不良妊娠史; 3.孕前合并糖尿病、高血压等疾病者; 4.随访期间确诊胎儿畸形、流产、早产者; 5.妊娠不足38周分娩者。

Exclusion criteria:

1. Fetal malformations; 2. Have a history of adverse pregnancy such as habitual miscarriage and preeclampsia in the past; 3. Patients with diabetes, hypertension and other diseases before pregnancy; 4. Patients diagnosed with fetal malformations, miscarriages, and premature births during the follow-up period; 5. Those who give birth at less than 38 weeks of pregnancy.

研究实施时间:

Study execute time:

From 2024-08-01 00:00:00 To 2027-07-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-08-15 00:00:00 To 2025-07-31 00:00:00

干预措施:

Interventions:

组别:

干预组

样本量:

60

Group:

Intervention group

Sample size:

干预措施:

线上线下相结合的方式进行体质量管理

干预措施代码:

Intervention:

Combining online and offline methods for body quality management

Intervention code:

组别:

对照组

样本量:

60

Group:

Control group

Sample size:

干预措施:

常规产检及健康教育

干预措施代码:

Intervention:

Routine birth check-up and health education

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

山东第二医科大学附属医院 

单位级别:

三甲 

Institution
hospital:

The Affiliated Hospital of Weifang Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

孕妇孕期体质量增长

指标类型:

主要指标

Outcome:

Pregnant women experience weight gain during pregnancy

Type:

Primary indicator

测量时间点:

孕38周

测量方法:

电子体重秤

Measure time point of outcome:

Pregnant at 38 weeks

Measure method:

Electronic weight scale

指标中文名:

妊娠期糖尿病及血糖控制情况

指标类型:

主要指标

Outcome:

Gestational diabetes mellitus and glycemic control

Type:

Primary indicator

测量时间点:

妊娠24-28周行葡萄糖耐量试验筛选出妊娠期糖尿病患者。并于妊娠30周、34周、36周、38周门诊产检时测空腹血糖,比较血糖控制情况。

测量方法:

采取血标本

Measure time point of outcome:

The patients with gestational diabetes were screened by glucose tolerance test at 24-28 weeks of ges

Measure method:

Blood sample

指标中文名:

分娩方式

指标类型:

次要指标

Outcome:

Delivery mode

Type:

Secondary indicator

测量时间点:

分娩时

测量方法:

病历查询

Measure time point of outcome:

At delivery

Measure method:

Case inquiry

指标中文名:

新生儿的体质量

指标类型:

次要指标

Outcome:

The body mass of the newborn

Type:

Secondary indicator

测量时间点:

新生儿出生时

测量方法:

病历查询

Measure time point of outcome:

At birth

Measure method:

Case inquiry

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 35 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

采用计算机产生的随机序列的方式进行随机分组

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomization was performed by means of computer-generated random sequences

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

单盲, 对受试者设盲

Blinding:

Single-blind, blinding subjects

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

原始数据可通过邮箱联系通讯作者获得

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The original data can be obtained by contacting the corresponding author by email

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

线上线下进行数据收集,线上采用查阅电子病历,线下采用问卷访谈采集数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection will be conducted both online and offline, using electronic medical records for online access and questionnaire interviews for offline data collection

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2025-02-07 10:42:21